financetom
Business
financetom
/
Business
/
Target Fiscal First-Quarter Results Miss Views; Gives Downbeat Earnings Outlook at Midpoint
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Target Fiscal First-Quarter Results Miss Views; Gives Downbeat Earnings Outlook at Midpoint
May 22, 2024 7:32 AM

10:12 AM EDT, 05/22/2024 (MT Newswires) -- Target's ( TGT ) fiscal first-quarter earnings unexpectedly declined, while the retailer issued a downbeat bottom line guidance at the midpoint for the ongoing three-month period.

The company's adjusted earnings fell to $2.03 a share for the quarter ended May 4 from $2.05 the year before, versus the Capital IQ-polled consensus of $2.06. Total revenue moved 3.1% lower to $24.53 billion. The Street's view was for $24.54 billion.

Comparable sales slid 3.7%, almost in line with what analysts were expecting, as the number of transactions decreased by 1.9%. "The average transaction was also down 1.9% as consumers continue to spend cautiously, particularly in discretionary categories," Chief Financial Officer Michael Fiddelke said on an earnings call, according to a Capital IQ transcript. The stock tumbled 8.5% in Wednesday's trading session.

Gross margin increased to 27.7% from 26.3% in the prior-year quarter amid cost improvements that more than offset higher promotional markdowns, according to the company. Selling, general and administrative expenses rose to $5.17 billion from $5.03 billion year-on-year.

"Our first-quarter financial performance was in line with our expectations on both the top and bottom line, tracking the trajectory we outlined for this year and setting up a return to growth in the second quarter," Chief Executive Brian Cornell said in a statement. "Our topline performance improved for the third consecutive quarter, with growth in our digital business led by strength in our same-day fulfillment services."

For the current quarter, Target ( TGT ) expects adjusted EPS between $1.95 and $2.35, while the Street is looking for normalized EPS of $2.18, which is above the outlook's midpoint of $2.15. Comparable sales are set to be in a range of flat to up 2% versus the market's estimate for a 1.6% gain.

"While this is below the growth rate we'd expect to deliver over time, it reflects the continued cautious approach to our near-term outlook, which has served us well in recent quarters," Fiddelke said on the call.

The retailer continues to project adjusted EPS of $8.60 to $9.60 for the full year with same-store sales flat to up 2%. The Street is currently looking for normalized EPS of $9.42 and comparable sales growth of nearly 1%. "We believe these ranges continue to properly show the range of scenarios we're completing given how the environment and our business has progressed so far this year," according to Fiddelke.

Price: 141.30, Change: -14.48, Percent Change: -9.30

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-VEON Sells 49% Stake In TNS+ For $137.5 Million
BRIEF-VEON Sells 49% Stake In TNS+ For $137.5 Million
May 28, 2024
May 28 (Reuters) - VEON Ltd: * VEON PROGRESSES WITH ASSET-LIGHT STRATEGY, REACHES AGREEMENT TO SELL STAKE IN TNS+ IN KAZAKHSTAN * VEON LTD - TOTAL CONSIDERATION FOR SALE IS USD 137.5 MILLION * VEON SELLS 49% STAKE IN TNS+ FOR $137.5 MILLION Source text for Eikon: Further company coverage: ...
Why Is AstraZeneca Stock Trading Lower On Tuesday?
Why Is AstraZeneca Stock Trading Lower On Tuesday?
May 28, 2024
On Tuesday, AstraZeneca Plc ( AZN ) said the survival results did not reach statistical significance in the overall trial population in the TROPION-Lung01 phase 3 trial. Topline overall survival (OS) results from the TROPION-Lung01 phase 3 trial, which previously met the dual primary endpoint of progression-free survival (PFS), numerically favored datopotamab deruxtecan (Dato-DXd) compared to docetaxel for locally advanced or metastatic non-small cell lung cancer (NSCLC)...
Glenfarne seeks five more years until 2029 to build Texas LNG export plant
Glenfarne seeks five more years until 2029 to build Texas LNG export plant
May 28, 2024
May 28 (Reuters) - U.S. energy company Glenfarne Group LLC has asked federal energy regulators for five more years until November 2029 to put its proposed Texas LNG export plant in Texas into service, according to a filing made available on Tuesday. Texas LNG is one of more than three dozen LNG export plants being developed in the U.S., Mexico...
Hess shareholders approve merger with Chevron
Hess shareholders approve merger with Chevron
May 28, 2024
HOUSTON (Reuters) - Hess Corp ( HES ) on Tuesday approved the company's $53 billion merger with the No. 2 U.S. oil company Chevron ( CVX ), according to preliminary results of the vote. The merger required a majority vote to approve the deal by a majority of Hess' 308 million shares outstanding to pass. The company did not immediately...
Copyright 2023-2026 - www.financetom.com All Rights Reserved